# Endothelial Cell Activation by SARS-CoV-2 Spike Protein and Its RBD: Central Player of the Immunothrobotic Response in COVID-19

**Authors:** Alan Cano-Mendez, Nallely Garcia-Larragoiti, Yesenia Ambriz-Murillo, Jennifer Velez-Chavez, Rogelio Vega-Agavo, Gerardo Vazquez-Marrufo, Ana Edith Higareda-Mendoza, Alejandra Ochoa-Zarzosa, Martha Eva Viveros-Sandoval

PMC · DOI: 10.3390/cimb48020161 · 2026-02-01

## TL;DR

This study shows how the SARS-CoV-2 Spike protein and its RBD activate endothelial cells, leading to inflammation and blood clotting in COVID-19.

## Contribution

The study identifies specific endothelial receptors and demonstrates a stronger response from the RBD compared to the full Spike protein.

## Key findings

- Endothelial cells exposed to the S protein and RBD showed increased release of immunothrombotic biomarkers.
- Molecular docking revealed potential interactions between the S protein and receptors like CD-141, CD-147, IL-6R, and TLRs.
- The RBD induced a stronger endothelial response compared to the full Spike protein.

## Abstract

COVID-19 has been associated with an active immunothrombotic process. The involvement of endothelial cells (ECs) in the feedback loop of the inflammatory and thrombotic process characteristic of COVID-19, as well as its differences with other infectious inflammatory conditions, remains an area requiring further elucidation. This study aimed to assess the immunothrombotic phenotype induced by the SARS-CoV-2 Spike (S) protein and its receptor-binding domain (RBD) in endothelial-derived cell lines. HUVEC and EA.hy926 cell lines were exposed to S protein and to its RBD. Inflammatory, thrombotic, and fibrinolytic mediators were quantified. Molecular docking assays were conducted to identify potential EC receptors for S protein. EC activation was dependent on both protein concentration and stimulation time. An increased release of immunothrombotic biomarkers were observed in endothelial-derived cells exposed to the S protein and to its RBD. The RBD induced a stronger endothelial response. Molecular docking demonstrated high affinity and a possible interaction between the S protein and endothelial receptors: CD-141, CD-147, IL-6R, TLR 2, 4, and 7. These findings confirm that the S protein and its RBD can induce an immunothrombotic phenotype in EC-derived cell lines, potentially exacerbating the disease pathology. We propose possible endothelial receptors mediating this response.

## Linked entities

- **Proteins:** l(3)62Bi (lethal (3) 62Bi), THBD (thrombomodulin), BSG (basigin (Ok blood group)), IL6R (interleukin 6 receptor), TLR2 (toll like receptor 2), TLR4 (toll like receptor 4), TLR7 (toll like receptor 7)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Genes:** F9 (coagulation factor IX) [NCBI Gene 2158] {aka F9 p22, FIX, HEMB, P19, PTC, THPH8}, ACE2 (angiotensin converting enzyme 2) [NCBI Gene 59272] {aka ACEH}, IL6R (interleukin 6 receptor) [NCBI Gene 3570] {aka CD126, HIES5, IL-1Ra, IL-6R, IL-6R-1, IL-6RA}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, PROC (protein C, inactivator of coagulation factors Va and VIIIa) [NCBI Gene 5624] {aka APC, PC, PROC1, THPH3, THPH4}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, VWF (von Willebrand factor) [NCBI Gene 7450] {aka F8VWF, VWD}, S (surface glycoprotein) [NCBI Gene 43740568] {aka spike glycoprotein}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, VTN (vitronectin) [NCBI Gene 7448] {aka V75, VN, VNT}, NRP1 (neuropilin 1) [NCBI Gene 8829] {aka BDCA4, CD304, NP1, NRP, VEGF165R}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, THBD (thrombomodulin) [NCBI Gene 7056] {aka AHUS6, BDCA-3, BDCA3, CD141, THPH12, THRM}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PLAAT4 (phospholipase A and acyltransferase 4) [NCBI Gene 5920] {aka HRASLS4, HRSL4, PLA1/2-3, PLAAT-4, RARRES3, RIG1}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, SERPINE1 (serpin family E member 1) [NCBI Gene 5054] {aka PAI, PAI-1, PAI1, PLANH1}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, PLAT (plasminogen activator, tissue type) [NCBI Gene 5327] {aka T-PA, TPA}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, SELP (selectin P) [NCBI Gene 6403] {aka CD62, CD62P, GMP140, GRMP, LECAM3, PADGEM}, SELPLG (selectin P ligand) [NCBI Gene 6404] {aka CD162, CLA, PSGL-1, PSGL1}, BSG (basigin (Ok blood group)) [NCBI Gene 682] {aka 5F7, CD147, EMMPRIN, EMPRIN, HAb18G, OK}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IVNS1ABP (influenza virus NS1A binding protein) [NCBI Gene 10625] {aka ARA3, FLARA3, HSPC068, IMD70, KLHL39, ND1}, ZMPSTE24 (zinc metallopeptidase STE24) [NCBI Gene 10269] {aka FACE-1, FACE1, HGPS, PRO1, RSDM1, STE24}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}
- **Diseases:** vasculopathy (MESH:D000090122), endothelial dysfunction (MESH:D014652), tumor (MESH:D009369), injury to (MESH:D014947), Inflammation (MESH:D007249), hemostatic (MESH:D020141), endothelial (MESH:D005642), long COVID (MESH:D000094024), immunothrombotic infectious diseases (MESH:D003141), coagulation disorders (MESH:D001778), infection (MESH:D007239), COVID-19 (MESH:D000086382), vascular injury (MESH:D057772), Thrombosis (MESH:D013927), abnormalities (MESH:D000014), deaths (MESH:D003643), virus (MESH:D014777)
- **Chemicals:** water (MESH:D014867), Metformin (MESH:D008687), ADP (MESH:D000244), streptomycin (MESH:D013307), EPI (MESH:D004837), calcium (MESH:D002118), CO2 (MESH:D002245), LPS (MESH:D008070), omeprazole (MESH:D009853), amikacin sulphate (MESH:D000583), Dulbecco's Modified Eagle Medium (-), S (MESH:D013455), penicillin (MESH:D010406)
- **Species:** Severe acute respiratory syndrome coronavirus 2 (no rank) [taxon 2697049], Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** A549 lung carcinoma — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), EA.hy296 — Homo sapiens (Human), Hybrid cell line (CVCL_3901), HUVEC — Homo sapiens (Human), Finite cell line (CVCL_3722), CRL-2922 — Homo sapiens (Human), Transformed cell line (CVCL_9L58)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939624/full.md

---
Source: https://tomesphere.com/paper/PMC12939624